Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.47)
# 941
Out of 5,090 analysts
86
Total ratings
42.05%
Success rate
7.68%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Buy | $60 | $26.36 | +127.62% | 1 | Dec 3, 2025 | |
| TRAW Traws Pharma | Initiates: Buy | $8 | $2.36 | +238.98% | 1 | Dec 3, 2025 | |
| CRDL Cardiol Therapeutics | Reiterates: Buy | $9 | $0.96 | +840.24% | 2 | Dec 1, 2025 | |
| CRMD CorMedix | Maintains: Buy | $17 → $18 | $10.62 | +69.57% | 4 | Nov 13, 2025 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $44 → $46 | $47.54 | -3.23% | 7 | Nov 7, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $10 | $6.72 | +48.92% | 3 | Nov 7, 2025 | |
| INDV Indivior | Maintains: Buy | $28 → $35 | $34.74 | +0.76% | 2 | Oct 30, 2025 | |
| RANI Rani Therapeutics Holdings | Assumes: Buy | $11 | $1.58 | +598.41% | 3 | Oct 21, 2025 | |
| OMER Omeros | Maintains: Buy | $9 → $20 | $10.98 | +82.15% | 3 | Oct 15, 2025 | |
| MNKD MannKind | Reiterates: Buy | $11 | $5.73 | +92.14% | 6 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.38 | +624.64% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $82.13 | +47.34% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $8.73 | +106.19% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.86 | +65.50% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.79 | +150.52% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $5.87 | +104.43% | 3 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.94 | +230.37% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.55 | +174.51% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $6.37 | +355.26% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $14.17 | +41.14% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $8.67 | +200.06% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.30 | +361.54% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $2.63 | +90.11% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $13.57 | +54.81% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.01 | +394.17% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.32 | +2,367.61% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $12.05 | +32.78% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $19.43 | +2,241.74% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $21.82 | +170.39% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $166.39 | +8.18% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.44 | +8,916.39% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $29.30 | +9.23% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.18 | +1,864,306.78% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $9.61 | +420.29% | 1 | Jul 12, 2018 |
Pelthos Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $60
Current: $26.36
Upside: +127.62%
Traws Pharma
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $2.36
Upside: +238.98%
Cardiol Therapeutics
Dec 1, 2025
Reiterates: Buy
Price Target: $9
Current: $0.96
Upside: +840.24%
CorMedix
Nov 13, 2025
Maintains: Buy
Price Target: $17 → $18
Current: $10.62
Upside: +69.57%
Collegium Pharmaceutical
Nov 7, 2025
Maintains: Buy
Price Target: $44 → $46
Current: $47.54
Upside: -3.23%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Buy
Price Target: $10
Current: $6.72
Upside: +48.92%
Indivior
Oct 30, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $34.74
Upside: +0.76%
Rani Therapeutics Holdings
Oct 21, 2025
Assumes: Buy
Price Target: $11
Current: $1.58
Upside: +598.41%
Omeros
Oct 15, 2025
Maintains: Buy
Price Target: $9 → $20
Current: $10.98
Upside: +82.15%
MannKind
Oct 13, 2025
Reiterates: Buy
Price Target: $11
Current: $5.73
Upside: +92.14%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.38
Upside: +624.64%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $82.13
Upside: +47.34%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $8.73
Upside: +106.19%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $7.86
Upside: +65.50%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.79
Upside: +150.52%
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $5.87
Upside: +104.43%
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $3.94
Upside: +230.37%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.55
Upside: +174.51%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $6.37
Upside: +355.26%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $14.17
Upside: +41.14%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $8.67
Upside: +200.06%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.30
Upside: +361.54%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $2.63
Upside: +90.11%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $13.57
Upside: +54.81%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.01
Upside: +394.17%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.32
Upside: +2,367.61%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $12.05
Upside: +32.78%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $19.43
Upside: +2,241.74%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $21.82
Upside: +170.39%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $166.39
Upside: +8.18%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.44
Upside: +8,916.39%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $29.30
Upside: +9.23%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.18
Upside: +1,864,306.78%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $9.61
Upside: +420.29%